Optical Genome Mapping Market: By Product (Instruments, Consumables & Reagents, Software, and Services), By Application (Structural Variation Detection, Genome Assembly, and Microbial Strain Typing), By End User (Academic & Research Institutes, Clinical Laboratories, and Biotechnology & Pharmaceutical Companies), and By Geography 

Optical Genome Mapping Market size was USD 132.1 million in 2023 and is expected to grow at a CAGR of 21.3% during the forecast period. Optical genome mapping (OGM) is a cutting-edge technology that enables high-resolution visualization and analysis of long DNA molecules for comprehensive structural variation detection and genome assembly. This market encompasses various tools and technologies essential for OGM, including specialized instruments, reagents, and software for data analysis. The OGM market serves a diverse range of applications in genomics research, clinical diagnostics, and drug discovery.

The growth of the OGM market is driven by factors such as increasing demand for advanced genomic analysis tools, rising prevalence of genetic disorders and cancer, and the limitations of traditional cytogenetic methods. For instance, according to the World Health Organization, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, emphasizing the need for advanced genomic analysis tools for better diagnosis and treatment. Moreover, the COVID-19 pandemic has accelerated the adoption of genomic technologies for pathogen surveillance and vaccine development, further boosting market expansion. However, challenges such as high instrument costs, the need for specialized expertise, and concerns about data interpretation may impact market growth to some extent.

Optical Genome Mapping Market Key Developments:

• In February 2022, Arima Genomics launched two new product offerings named Arima-HiC+ FFPE kit in which scientists will be able to find and discover structural variants in their 3D genomic data with this tool. By combining structural variant detection with 3D genome orientation data, researchers will gain a better understanding of how variants affect gene and cellular function. Finally, these findings will benefit scientists in the discovery of novel disease mechanisms and therapeutic targets.
• In October 2021, Bionano Genomics announced the acquisition of BioDiscovery, leading software company with high-class solutions for the analysis, interpretation, and reporting of genomics data. The Bionano and BioDiscovery teams will collaborate to create a version of NxClinical that includes optical genome mapping data alongside existing next-generation sequencing and microarray data types. Future goals include RNA expression profiling, epigenetics including methylation, and maybe proteomics in the future.